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Estimation is a widely used method of assessing the weight of patients with acute 
stroke. Because the dosage of tissue plasminogen activator (tPA) is weight-dependent, 
errors in estimation lead to incorrect dosing. 
Methods: 
We installed a ground-level scale in the computed tomography (CT) suite of our 
hospital and integrated a scale into the CT table of our Mobile Stroke Unit in order to 
prospectively assess the differences between reported, estimated, and measured 
weights of acute stroke patients. An independent rater asked patients to report their 
weight. The patients’ weights were also estimated by the treating physician and 
measured with a scale. Differences between reported, estimated, and measured 
weights were analyzed statistically. 
Results: 
For 100 consecutive patients, weighing was possible without treatment delays. 
Weights estimated by the physician diverged from measured weights by 10% or more 
for 27 patients and by 20% or more for 6 patients. Weights reported by the patient 
diverged from measured weights by 10% or more for 12 patients. Weights reported by 
the patients differed significantly less from measured weights (mean, 4.1 ± 3.1 kg) than 
did weights estimated by the physician (5.7 ± 4.4 kg; p = 0.003). 
Conclusion: 
This first prospective study of weight assessment in acute stroke shows that the use of 
an easily accessible scale makes it feasible to weigh patients with acute stroke without 
the treatment delay associated with additional patient transfers. Physicians’ estimates 
of patients’ weights demonstrated substantial aberrations from measured weights. 






Die Schätzung ist eine weit häufig benutzte Methode zur Beurteilung des Gewichts von 
Patienten mit akutem Schlaganfall. Da die Dosierung von 




Wir installierten eine Bodenwaage in der Computertomographie-Suite (CT) unseres 
Krankenhauses und bauten eine Waage in die CT-Tabelle unserer Mobile Stroke Unit 
ein, um die Unterschiede zwischen den berichteten, geschätzten und gemessenen 
Gewichten von Patienten mit akutem Schlaganfall prospektiv zu bewerten. Ein 
unabhängiger Bewerter bat die Patienten, ihr Gewicht anzugeben. Das Gewicht der 
Patienten wurde ebenfalls vom behandelnden Arzt geschätzt und mit einer Skala 
gemessen. Die Unterschiede zwischen berichteten, geschätzten und gemessenen 
Gewichten wurden statistisch analysiert. 
 
Ergebnisse: 
Bei 100 aufeinanderfolgenden Patienten war ein Wiegen ohne 
Behandlungsverzögerungen möglich. Die vom Arzt geschätzten Gewichte weichen bei 
27 Patienten um 10% oder mehr und bei 6 Patienten um 20% oder mehr ab. Die vom 
Patienten berichteten Gewichte weichen bei 12 Patienten um 10% oder mehr vom 
gemessenen Gewicht ab. Die von den Patienten angegebenen Gewichte unterschieden 
sich signifikant weniger von den gemessenen Gewichten (Mittelwert 4,1 ± 3,1 kg) als 
die vom Arzt geschätzten Gewichte (5,7 ± 4,4 kg; p = 0,003). 
 
Schlussfolgerung: 
Diese erste prospektive Studie zur Gewichtsbewertung bei akutem Schlaganfall zeigt, 
dass die Verwendung einer leichten zugänglichen Waage das Wiegen von Patienten 
mit akutem Schlaganfall ohne die mit zusätzlichen Patiententransfers verbundene 
Behandlungsverzögerung möglich macht. Die Schätzungen der Ärzte zum Gewicht der 
Patienten zeigten erhebliche Abweichungen von den gemessenen Gewichten. Das 
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Stroke is an acute neurological disfunction caused by acute focal injury of the central 
nervous system (CNS) attributed to a vascular cause together with cerebral infarction, 
intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH). 
Worldwide stroke is a major cause of disability and death. 
 
Despite its global impact in clinical research, or in assessments of the public health, the 
term “stroke” is not consistently defined in clinical practice. 
 
Due to the development in basic science, neuropathology, and neuroimaging we have 
improved our understanding of ischemia, infarction, and hemorrhage in the CNS. 
Based upon the underlying pathological mechanism, there are several types of stroke, 
and classifying strokes correctly is fundamental for correct treatment of patients. 





Table 1: Definition of Stroke (1) (Stork 2013). 
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1.1.2 . History of Definition of Stroke 
 
The term “stroke” was first introduced into medicine in 1689 by William Cole in A 
Physico-Medical Essay Concerning the Late Frequencies of Apoplexies. (2). Before that 
“apoplexy” was used by Hippocrates circa 400 BC to describe very acute nontraumatic 
brain injuries. For >2000 years, neurologists sought to find the exact definition of 
term “stroke.” (3). 
The term “transient ischemic attack” has been used by neurologists since the 1950s, 
to define the temporary vascular-related episodes of brain dysfunction which could 
not qualify as strokes. 
Neurologists sought to arrive a generally consensus definitions of stroke and TIA 
because of great advance of information about the brain and its function, anatomy, 
and blood supply during the past 200 years. Physicians and other specialists in brain 
diseases have increased their understanding during the past 55 years. During the past 
35 years, the ability to safely and quickly image the brain and its blood-supplying 
vessels in patients has become a reality. And, in the past 15 years, modern vascular 
and brain imaging has become available in most hospitals. 
The current World Health Organization definition of stroke “rapidly developing clinical 
signs of focal (or global) disturbance of cerebral function, lasting more than 24 hours 
or leading to death, with no apparent cause other than that of vascular origin” was 
first used in 1970. (4). 
An updated definition is required because of the great advance in knowledge about 
the nature, timing, clinical recognition of stroke since this definition was formulated. 
In the Second Princeton Cerebrovascular Disease Conference in 1957, C.M. Fisher 
presented an extensive characterization for what he termed “transient ischemic 
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attacks,” that “may last from a few seconds up to several hours, the most common 
duration being a few seconds up to 5 or 10 minutes”. (5). 
 
During the Fourth Princeton Cerebrovascular Disease Conference in 1965, the term 
“transient ischemic attack” was announced as the preferred term for temporary 
episodes of brain and eye ischemia. (6). 
The definition of transient ischemic attacks as “episodes of temporary and focal 
dysfunction of vascular origin, which are variable in duration, commonly lasting from 
2 to 15 minutes, but occasionally lasting as long as a day (24 hours). They leave no 
persistent neurological deficit” was published in 1975, an Ad Hoc Committee on 
Cerebrovascular Disease. (7). 
When this definition of transient ischemic attack with 24 hours of symptom duration 
in 1975 was published, the diagnostic techniques that could determine the presence 



























Figure 3: CT: intracerebral hemorrhage in hypertension in typical locations.( Neurology 2016). 
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1.1.3 General overview 
 
Stroke is one of the most common and expensive diseases. Stroke is 
 
more common in most countries today than heart attacks. Nevertheless, the 
level of knowledge about the stroke is much less pronounced than for other 
diseases. 
Public awareness and presence in the media are accordingly limited. 
 
Every stroke is an emergency but it has not always been treated as such in the past. 
 
In most internal emergency departments, the stroke patient has often a lower priority 
compared to heart attack, trauma, acute abdomen, epileptic seizure or acute 
psychosis. (8). 
Since effective acute therapies have become available, the acute stroke patient 
receives higher priority. 
Stroke is the most common disease in most neurological clinics. Up to 50% of all 
inpatients in these clinics have a vascular disease of the nervous system. 
As in other fields of modern medicine, advances in diagnosis and therapy have greatly 
changed the care structure. Patients come to the clinic more quickly, are diagnosed as 
an emergency and treated at modern stroke units. 
There are effective treatments and the prognosis is much better than it was 10 years 
ago. 
Stroke Units developed in Germany more than in any other region of the world. There 
are more than 250 Stroke Units in Germany. 
There is hardly an area of clinical medicine that is so strongly influenced by German 




Stroke is one of the most common diseases worldwide, the leading cause of permanent 
disability and, from a medical-economic perspective, among the most expensive 
diseases in Western industrialized countries. (10). 
Worldwide, stroke is behind infectious diseases but still ahead of cancer and other 
cardiovascular diseases, as a cause of death. It is the leading cause of death in China, 
India, Russia and Brazil. (8). 
According to  the  World  Health  Organization  (WHO)  stroke  in  2016  was  
classified as the second leading  cause  of  death  after  ischemic  heart  disease.  
More than 17 million strokes are reported worldwide and stroke is responsible for 
more than 6.5 million deaths each year, two thirds of them in developing countries. 
(11). 
The incidence of cerebral infarction in Germany is approx. 220 per 100 000 inhabitants 
per year and transient ischemic attack (TIA) 90 per 100 000 per year, the Male to 
Female ratio is approximately 1.3 to 1 but from age 80 is approximately 1 to 1. 
Incidence increases gradually with age (from 75 years, for example, 1200 infarctions 
and 500 TIA / 100,000 inhabitants / year). It is expected a continuous increase of about 









 Males Females total 
First – time Stroks 88087 108339 196426 
Repeated Strokes 29597 36492 65999 
total 117684 144741 262425 
 
Table 2: Estimated Stroke Incidence in Germany. 
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1.1.5 Outcome after stroke 
 
In Germany, stroke is the third leading cause of death after cardiac and cancer 
diseases.. 
In 2008, the official cause of death statistics reported stroke as the cause of death in 
approximately 63,000 deaths. 
The age-adjusted stroke mortality rates in the German population show a significant 
decline in men and women in recent years. 
Stroke is the leading cause of acquired disability in adults (14). 
Three months after the event, about 25% of surviving patients have severe limitations 
in activities of daily living (defined as Barthel Index <60). (Ward et al ,.2005) and ca.17% 






Figure 5 : Development of stroke mortality in Germany between 1998 and 2008 
 
(official cause of death statistics Germany 2008 (www.statis.de), directly age-standardized rates using 





Ischemic stroke is a major concern to the public health due to the high mortality rate 
and long-term disabilities that affect patients after stroke. According to published data, 
within 30 days of experiencing a stroke, the mortality rate is between 16% and 22% 
(16); this number increases to 29% within 1 year. 
Furthermore, approximately 31% of patients that survive strokes need assistance in 
caring for themselves (17). However, the prognosis after stroke varies widely across 
individual patients depending on a multitude of factors that have a great impact on 
functional outcomes after stroke. Here, we summarize the factors that are considered 





Stroke severity is clinically estimated based on the degree of neurological impairment, 
infarction location, and the size of location which are assessed by neuroimaging such 
as MRI and CT. 
There are several ways and scales to evaluate the neurological impairment of ischemic 
stroke patients, because Stroke severity is a major factor in predicting the outcome of 
patients after stroke (18). 
As an example, National Institute of Health Stroke Scale (NIHSS), Canadian 
Neurological Scale (CNS) and Middle Cerebral Artery Neurological Score (MCANS) are 
the most common scales to evaluate stroke severity and modified Rankin Scale (mRS). 
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NIHSS is a well-known and widely-used scale because it considers the overall degree 
of neurological deficits and can accurately predict the stroke outcome, especially in 
the first three months (19). 
It has been shown in the literature that the odds of excellent outcome decrease by 
17% for each additional point on the NIHSS scale (20). Moreover, it also has been 
shown that patients with NIHSS scale ≤6 are more likely to recover well after stroke. 
Patients with a score of NIHSS measured ≥16 are more like to have unfavorable 
outcome (21). 
A- Modified Rankin Scale (mRS). (22.23.24). 
 
The Modified Rankin Scale (mRS) is a scale used to measure the degree of disability in 
patients who have had a stroke, as follows: 
0: No symptoms at all 
 
1: No significant disability despite symptoms; able to carry out all usual duties and 
activities 
2: Slight disability; unable to carry out all previous activities, but able to look after own 
affairs without assistance 
3: Moderate disability; requiring some help, but able to walk without assistance 
 
4: Moderately severe disability; unable to walk without assistance and unable to 
attend to own bodily needs without assistance 




B- The National Institutes of Health Stroke Scale form used by Providence Health 
System (NIHHS SCORE). 
 










1a. Level of 
Consciousness 





     
1b. LOC Questions 
(Month, age) 
0= Answer both correctly 
1= Answer one Correctly 
2= Incorrect 
     




0= Obeys both correctly 
1= Obeys one correctly 
2= Incorrect 
     
2. Best Gaze (Eyes open 
– patient follows 
examiner´s finger or 
face) 
0= Normal 
1= Partial gaze palsy 
2= Forced deviation 
     
3. Visual Fields (Inroduce 
visual stimulus/ threat to 
pt´s visual field 
quadrants) 
0= No visual loss 
1= Partial Hemianopia 
2= Complete Hemianopia 
3= Bilateral Hemianopia(blind) 
     
4. Facial Paresis 
(Show teeth, raise 
eyebrows 






     
5a. Motor Arm - Left 
5b. Motor Arm – Right 
(Elevate arm to 90° if 
patient is sitting, 
45° if 
supine) 
0= No drift 
1= drift 
2= Can´t resist gravity 




(Joint fusion or limb 
amp) 
Left      
Right      
6a. Motor Leg - Left 
6b. Motor Leg – Right 
(Elevate Leg 30° with 
patient supine) 
0= No drift 
1= Drift 
2= Can´t resist gravity 
3= No effort gravity 
4= No movement 
X= Untestable 
(Joint fusion or limb 
amp) 
Left      
Right      
7. Limb Ataxia 
(Finger nose, heel 
down 
shin) 
0= No ataxia 
1= Present in one limb 
2= Present in two limbs 
     
8. Sensory (Pin prick to 
face, arm, trunkand leg – 
compare side to side) 
0= Normal 
1= Partial loss 
2= Severe loss 
     
9. Best Language (Name 
item, describe a Picture 
and read sentences) 
0= No aphasia 
1= Mild to moderate aphasia 
2= Severe aphasia 
3= Mute 
     
10. Dysarthria 
(Evaluate speech 
clarity by Patient 
repeating listed 
words) 
0= Normal articulation 
1= Mild to moderate slurring of 
words 
2= Near to unintelligible or 
worse 
X= Intubated or other physical 
barrier 
     
11. Extinction and 
Inattention 
(Use information from 
prior testing to identify 
neglect or double 
0= No neglect 
1= Partial neglect 
2= Complete neglect 




      
 




There are two major mechanisms for ischemia in brain: thromboembolism and 
hemodynamic failure. 
Thromboembolism caused by embolism or in situ thrombosis and leads to a decrease 
in regional cerebral blood flow (CBF). 
Hemodynamic failure caused by arterial occlusion or stenosis, when collateral blood 
supply fail to maintain CBF at sufficient levels to preserve the brain function under 
some circumstances that decrease perfusion proximally to the arterial lesion (systemic 
hypotension or low cardiac output) and increase metabolic demands (fever, acidosis) 
or conditions that lead to ‘‘steal’’ of blood from affected to unaffected areas in the 
brain (carbon dioxide retention) (25). 
 
 
1.2.3.1 Normal cerebral blood flow 
 
Although the brain accounts for only 2% of body weight, it receives about 15% (about 
1.2 l) of cardiac output in rest and consumes about 20% of the body's total O2 
requirement  (about  3.35  ml  of  oxygen  per  100  g  of  brain  tissue  per  minute).  
In a healthy adult, cerebral blood flow (CBF) is approximately 60-80 ml per 100 g of 
brain tissue per minute.(8). 
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1.2.3.2 Cerebral blood flow changes in ischemia 
 
The main factors that ultimately determine the tissue outcome after vessel occlusion 
are regional CBF and duration of vessel occlusion. 
A decrease in regional CBF leads to diminished tissue perfusion. Local perfusion 
pressure is the main factor that influence the eventual outcome of tissue in persistent 
large vessel occlusion (26) and depends on several factors such as systemic arterial 
pressure and the presence and extent of collaterals (as a result to loss of the ischemic 
brain’s autoregulatory capacity). 
 
 
1.2.3.3 Cerebral Blood Flow Thresholds in Cerebral Ischemia 
 
The tissue outcome following arterial occlusion varies according to the concept that 
CBF thresholds exist, below which neuronal integrity and function are differentially 
affected. 
Early human studies conducted in the 1950s during carotid artery endarterectomy 
found that hemiparesis occurred when regional CBF fell below 50% to 30% of normal, 
and permanent neurologic deficit occurred if mean CBF fell below 30% of normal 
during clamping of carotid by using intracarotid xenon 133 injections (27). 
The development of permanent neurologic sequelae is a time-dependent process. 
 
Low cerebral blood flow are tolerated only for a short period of time, while higher 




Figure 6: Schematic drawing of the different cerebral blood flow thresholds. (30). 
 
The relationship between the cerebral blood flow threshold and focal cerebral 
ischemia proposed by landmark studies performed by Symon and colleagues (1977), 
who investigated the relationship between severity of decreased cerebral blood flow 
and degree of neurologic dysfunction at various durations of ischemia in a baboon 
model of middle cerebral artery occlusion. They proved that brain tissue perfusion 
between certain cerebral blood flow (22 mL/ 100 mg/min to 8 mL/100 mg/min) 
maintains brain tissue structural integrity and can be reversed with reperfusion even 
when prolonged hypoperfusion stops functioning. 
1981 Johns and colleagues proved that permanent or transient neurologic deficit is 
time dependent, they proved that the cerebral blood flow values below which brain 
tissue becomes infarcted are dependent on the duration of vessel occlusion by using a 
temporary or permanent middle cerebral artery occlusion. (31). 
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1.2.3.4 Concept of Ischemic Core and Ischemic Penumbra 
 
Astrup and colleagues (1981) first introduced the concept of ischemic core and 
ischemic penumbra. This concept supposes that in acute stroke, the tissue supplied by 
the occluded artery is compartmentalized into areas of irreversibly damaged brain 
tissue and areas of brain tissue that are reversibly damaged. 
The ischemic core represents tissue that is irreversibly damaged. PET studies in 
humans suggest the ischemic core corresponds to cerebral blood flow values of less 
than 7 mL/100 mg/min to 12 mL/100 under a limited time (probably no longer than an 
hour (32, 33, 34). 
The ischemic penumbra represents tissue that is functionally impaired but structurally 
intact and remediable. It corresponds to a high cerebral blood flow between 17 
mL/100 mg/min to 22 mL/100 mg/ min and 7 mL/100 mg/min to 12 mL/100 mg/min. 
(35.36) 
The aim of acute stroke therapy is to rescue this tissue by raising its flow to non- 
ischemic levels. It is proved that under normal circumstances this tissue is not at risk 
of infarction (26). 
It is supposed that under certain circumstances, such as hypotension, fever, or 






Figure 7: Thresholds of metabolic (left) and electrophysiologic (right) disturbances during gradual 
reduction of cortical blood flow. SEP = somatosensory evoked potentials 
 






Figure 8: Experimental model of middle cerebral artery occlusion in rats. 
 
Serial MRIs (coronal sections) at three levels in the brain depicting the apparent diffusion coefficient of 
water (ADC) (blue) demonstrating the time-dependent growth of the ischemic core. (37). 
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1.2.4 . Treatment acute ischemic Stroke 
 
The therapy of acute ischemic stroke has been massively developed in the past 2 
decades. It is possible with new treatment options to reverse ischemia und enable 
patients to work again whereas previous destined to severe disability or death. IV 
thrombolysis therapy that began 20 years ago, mechanical thrombectomy and 
endovascular treatment had improved outcomes in patients with severe neurologic 
deficits from a proximal intracranial vessel occlusion. (38). 
There are three main principles of acute stroke care: 
 
1) achieve timely recanalization of the occluded artery and reperfusion of the ischemic 
tissue. 
2) optimize collateral flow. 
 
3) avoid secondary brain injury. 
 
Recanalization and reperfusion are the optimal therapy of acute stroke treatment to 
reduce infarct size and reverse neurologic deficits. 
Recanalization is defined by the degree of reopening of the occluded artery. Reopening 
the occluded artery help to recover the hypoperfused brain tissue that is not 
sufficiently perfused. This tissue represents the ischemic penumbra that can be 
salvaged if adequate blood flow is promptly reestablished. Nowadays advanced CT 
perfusion or magnetic resonance (MR) diffusion/perfusion can exhibit this tissue at risk 
(penumbra imaging) (39). Reperfusion is measured by the degree of flow reaching the 
previously hypoperfused brain tissue. The two evidence-based strategies to achieve 
reperfusion are: 
1- chemical thrombolysis with recombinant tissue plasminogen activator (rtPA), also 
known as alteplase. 






Figure 9: B: Cerebral blood flow image of the CT perfusion disclosing hypoperfusion throughout the left 
middle cerebral artery distribution. C, Cerebral blood volume image of the CT perfusion showing no 
definite areas of established infarction. (38). 
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1.3 Tissue plasminogen activator (tPA). 
1.3.1 General Overview 
 
tPA is a protein that helps in the breakdown of blood clots. It is a serine protease found 
on endothelial cells in blood vessels. tPA works as the major enzyme in catalyzing the 
conversion of plasminogen to plasmin and to clot breakdown. Human tPA has a 
molecular weight of ~70 kDa in the single-chain form. (40). 
tPA was first produced by recombinant DNA techniques in 1982. 
 
After a cDNA library was established with the use of reverse transcriptase and mRNA 
from human melanoma cells. 
Tissue-type plasminogen activators were initially identified and isolated from 
mammalian tissues. (41). 
tPA was the first pharmaceutical produced synthetically with the use of mammalian 
cells, specifically Chinese hamster ovarian cells. 
Recombinant tPA is commonly referred to as r-tPA and sold under multiple brand 
names. (42). 
In 1996 after the positive National Institute of Neurological Disorders and Stroke 
(NINDS)-2 trial, Recombinant t-PA (rt-PA) was approved for acute ischemic stroke, and 
until now is the only established choice as acute thrombolytic treatment in acute 
ischemic stroke. (43). 
Despite the great progress in last years in imaging techniques and the introduction of 
stroke care units, many patients are left untreated because of the narrow time window 
of 4.5 hours, unknown onset, lack of awareness, and a high number of exclusion 






Figure 10: A theoretical structure of the full t-PA enzyme in humans. 
 
Sugar residues are the light cyan-grey molecules, and the different domains are marked in different colors. 
(40). 
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1.3.2 Early Development of Thrombolytics 
 
Tillett and Garner discovered in 1933 that certain strains of Streptococcus could 
dissolve fibrin clots (45).The role of fibrinogen was supposed through serendipity: 
streptococci agglutinated in human serum but not in plasma (46). 
In 1955 Tillett proved the clinical effectiveness of streptokinase (SK) in patients with 
extracranial occluding vascular thrombi (47).In the 1940s, Macfarlane and Pilling 
discovered the fibrinolytic potential of human urine, leading to extraction of urokinase 
(UK), a strong activator of plasminogen to form plasmin (48). 
Staphylokinase was isolated by Lack from Staphylococcus strains (50). 
 
In 1958 Sussman and Fitch reported to first time about the use of a thrombolytic agent 
for acute ischemic stroke (51). 
They treated 3 patients with intravenous plasmin (fibrinolysis) daily for 4–6 days; only 
1 patient showed clinical improvement. 
The early studies of treatment with thrombolytic therapy for acute ischemic stroke 
using either SK or UK did not exhibit a benefit, however, intra cerebral hemorrhage 
was a leading cause of death (52). 
These led to limitations in study design and technology. After the development in 
imaging technology a limited number of pilot studies were performed using 
angiography as a diagnostic method. A placebo-controlled pilot study was conducted 
in 1963 by Meyer et al. 
(53) This study compared the administering intravenous plasmin with placebo over 4 
h daily for 3 days in 40 patients with middle cerebral artery occlusion. No differences 
between the both treatment groups were found. 
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1964 a subsequent trial in 73 patients with progressive stroke of using streptokinase 
plus heparin showed a higher mortality and intra cerebral hemorrhage rate than 
heparin alone (54). 
It could be argued that intra cerebral hemorrhage could already have been present at 
admission, because computer tomography (CT) was first available in 1970. Later 
streptokinase was abandoned for the treatment of acute cerebral ischemia due to high 
intra cerebral hemorrhage rate (55,56). 
The advances in neuro-imaging technic by CT scanning led to the initiation of new 
investigations in the 1980s. 
Fujishima 1968 conducted a study on 143 patients treated with either urokinase or a 
combination of urokinase and dextran sulphate. Clinical improvement and safety of 











Figure 11: In vivo mechanism of action of tPA within the fibrinolytic system. 
 
tPA can go one of three ways in the body; (1) uptake by the liver and clearance through 
receptors therein, (2) inhibition by a plasminogen activator inhibitor (PAI) and 
subsequentl hepatic clearance, or (3) through the activation of plasminogen to plasmin 












Figure 12:. The first publication with a thrombolytic agent in stroke (JAMA,1958), (58). Reproduced with 
permission by the publisher. 
29  
1.3.3 Tissue Plasminogen Activator 
 
The first study with t-PA in patients with acute myocardial infarction was reported in 
1983, leading to good results with recanalization in 6 out of 7 patients (59). The 
dramatic development came later in that year when rt-PA was obtained by expression 
of the cloned gene in a mammalian cell system (60). 
After the publication of the GUSTO-I trial (a study that randomized over 40,000 
patients to combinations of SK or rt-PA with heparin), a Large-scale use of rt-PA in 
acute myocardial infarction had started. This trial proved that rt-PA is superior to SK. 
(61). 
Terashi was the first person who used rt-PA in a trial in AIS in 1990(62), 364 patients 
were treated with either rt-PA or urokinase. He found no differences between the two 
groups. 
In 1992 two pilot studies, sponsored by the NINDS performed by using escalating doses 
of 0.35–1.08 mg/kg rt-PA in a total of 94 patients and a time window up to 3 h after 
onset (62,63). 
The subsequent major NINDS-2 trial, published in 1995, showed that 0.9 mg/kg IV. rt- 
PA, administered within 3 h of symptom onset to patients with acute cerebral ischemia 
led to an improvement clinical outcome at 3 months compared to patients who 
received placebo, the risk of symptomatic intracerebral hemorrhage was 6.4% (64). 
The Food and Drug Administration approved in 1995 the use of rt-PA in AIS patients 
depending on the outcome of the NINDS-2. 
The ECASS-1/2/3, ATLANTIS-A/B and EPITHET trials investigated between 1998 and 
2008 the safety and efficacy of rt-PA in acute cerebral ischemia, only the ECASS-3 
reported a benefit. (65-70) 
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A pooled analysis, performed by Lees et al. (71) in 2010, showed a moderate benefit 
for rt-PA between 3 and 4.5 h, with greater benefit with earlier use. This finding was 
confirmed in a Canadian rt-PA registry 2011 (72, 73). 
To date, rt-PA is still the only licensed thrombolytic agent for acute cerebral stroke, the 
dose is of 0.9 mg/kg, administered starting with an intravenous bolus of 10% of dose, 
followed by intravenous infusion of the rest of the dose over 60 min, according to the 
NINDS study criteria (64). 
In 2009, the American Heart Association Stroke Council published, recommendation 
to treat the patients with rt-PA within the time period of 3–4.5 h after onset of ischemic 
stroke when additional criteria are taken into account (71). They are depending on the 
results of the ECASS-3 trial (66), the outcome of the pooled analysis performed by Lees 
et al (67), and the publications from the SITS-ISTR registry (75,76). 
In 2011, rt-PA approved by the European Medical Agency for its use up to 4.5 h after 
onset with exclusion patients older than 80 years. 
However, recent evidence supports the use of intravenous thrombolysis in patients 
aged over 80 years as well as in patients with diabetes and prior stroke if they 
otherwise fulfil treatment criteria (77,80). 
The Food and Drug Administration has not extended the license time window more 
than 3 h. In Japan, rt-PA with low dose (0.6 mg/kg i.v.) was approved in 2005 for use 
up to 3 h after onset (78) , and extended to 4.5 h in 2012. 
Twenty-Year history of the evolution of stroke thrombolysis with intravenous Alteplase 
to reduce long-term disability was published on 7. Jul. 2015 compared the result of 
National Institute of Neurological Disorders and Stroke (NINDS) and the 6 further 
randomized trials that compared tPA and placebo in various time windows 0 to 6 hours 
from stroke symptom onset (Table 4). 
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This meta-analysis proved the generalized efficacy of tPA in the 0- to 4.5-hour time 
window, regardless of baseline stroke severity or age, with maximal benefit with 
treatment time (83). 
 
 
Table 4: Randomized Trials of Alteplase vs Placebo. (83). 
 
Data extracted from Cochrane systematic review (84) ATLANTIS indicates Alteplase 
Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke; CI, confidence 
interval; ECASS, European Cooperative Acute Stroke Study; EPITHET; Echoplanar 
Imaging Thrombolytic Evaluation; 
*Alteplase dose 1.1 mg/kg; all other trials 0.9 mg/kg. 
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Intravenous recombinant tissue plasminogen activator (rt-PA) in acute ischemic stroke 
is weight-based dosing. The standard dose of IV rtPA for acute ischemic stroke is 0.9 
mg/kg, 10% administered as a bolus and the remainder infused over 1 hour. (85). The 
maximal dose should not be more than 90 mg, for that potential medication dosing 
errors may affect the relative risks and benefits of this therapy. 
Weight is usually estimated by the patient, the family, the nurse, or the treating 
physician. Difference between actual and estimated weight leads to an incorrect dose 
and may adversely influence outcome. 
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1.4 Mobile stroke unit (MSU) 
The treatment of stroke should be initiated as soon as possible because of the narrow 
therapeutic time window. Until now many patients still fail to reach the hospital within 
the narrow time window to receive maximum treatment to benefit from advanced 
stroke therapies, including recombinant tissue plasminogen activator (tPA) and 
mechanical thrombectomy. (86). 
The great advance of emergency medical services, telemedicine, and mobile 
technology, including transportable computed tomography scanners, has presented 
the idea to decrease the time of therapy in acute stroke with a mobile stroke unit 
(MSU)(86). 
The Mobile Stroke Unit MSU is an ambulance, equipped with a CT scanner and point 
of care laboratory unit and accompanied by a neurologist and neuroradiologist. 
Neurologists can directly conduct the patient's medical history the physical 
examination, blood sample analysis and the neuroradiologist immediately performs 
the CT scan. (87). 
The thrombolytic therapy will directly be started by the neurologist if the inclusion and 
exclusion criteria are fulfilled. (88). 
The Mobile Stroke Unit concept was first published in 2003 and was realized in clinical 
practice in 2008 by Fassbender et al. at Saarland University, Germany (89). Fassbender 
et.al. (2003) shows that Thrombolysis in <1 hour could become possible with the 
mobile stroke unit which enables the starting of treatment immediately without losing 
time by transport to and within the hospital. Walter et.al (2018) reported a marked 
advantage for the Mobile Stroke Unite in decreasing treatment times (91). The second 
MSU was launched in Berlin, Germany in July 2011(92). The first MSU in United States 
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was established in Houston in May 2014 after the promising results from Homburg and 
Berlin (93). 
 























Figure 15: Active MSU Sites with Research Programs (95). 
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2 Material and Method 
 
2.1 Introduction 
Although several recent trials have achieved positive results with mechanical 
recanalization after acute ischemic stroke with large-vessel occlusion (96–100), 
intravenous thrombolysis (IVT) is still the most important acute treatment for the vast 
majority of ischemic stroke patients (101–104). The dosage of tissue plasminogen 
activator (tPA) depends on the patient’s weight: the approved dosage is 0.9 mg/kg to 
a maximum dose of 90 mg. However, uncertainties remain whether the current dosage 
regimen is optimal. Most reports of randomized controlled trials have not stated how 
patients’ weights were assessed or whether weights were only estimated; only the 
report of the European Cooperative Acute Stroke Study II (ECASS II) states that most 
weights were estimated (103). More precise data were presented in the Safe 
Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis (SITS- 
ISTR) Registry: 14.6% of patients’ weights were measured, whereas the remaining 
were estimated (105). Clinical surveys have shown that health care professionals most 
commonly assess a patient’s weight by asking the patient or the patient’s caregiver or 
by roughly estimating the patient’s weight (106). Only a small minority of hospitals 
actually weigh the patient before thrombolysis is administered. Findings about 
whether inaccurate assessment of weight affects clinical outcomes are mostly 
retrospective and sometimes contradictory. However, a growing body of evidence 
suggests that imprecise dosage may negatively influence outcome (107–109). 
No prospective trials have determined the accuracy of weights reported by the patient 
or estimated by the treating medical staff in the acute setting. When asked, clinicians 
argue that weighing the patient is either time consuming or impossible because of the 
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patient’s immobility and the need to transfer the patient in a seated or upright 
position. However, these limitations can now be overcome by ground-level scales that 
allow the patient and the emergency medical service stretcher to be placed directly on 
the scale, without patient transfer. In addition, certain computed tomography (CT) 
tables now contain an integrated scale. After the implementation of a ground-level 
scale in our hospital and the integration of a scale into the CT table of our Mobile Stroke 
Unit (110), we prospectively compared the weights reported by the patients, those 
estimated by health care professional and those measured with a scale. 
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2.2 Methods 
Patients with suspected acute stroke or transient ischemic attack who were admitted 
to our hospital were included in this study. Written informed consent was obtained 
from all patients or their caregivers before the study. The study was performed in 
accordance with our clinical ethical guidelines and was approved by the ethics 
committee of the Chamber of Physicians of the Saarland. 
 
 
2.2.1 Measuring Weight with the Ground-Level 
Scale: 
In our hospital, patients are admitted to the CT suite, which contains a point-of-care 
laboratory so that treatment delays can be reduced (111). A ground-level scale 
(Soehnle, Nassau, Germany; Fig. 16a) was installed in this suite so that paramedics can 
place the patient directly onto it upon entering the room. Thus, the patient is weighed 
together with the stretcher. The patient is then transferred to the CT table, and the 
weight of the stretcher is determined with the ground-level scale. The difference 
between the two results is the patient’s weight. Treatment delays are avoided by 
measuring weight during the handover of the patient from the emergency physician 
to the treating neurologist. 
 
 
2.2.2 Measuring Weight in the Mobile Stroke Unit: 
 
In the Mobile Stroke Unit, a scale (Soehnle, Germany; Fig. 16b) has been integrated 
into the CT table. Medical equipment such as monitors is removed from the stretcher 
during weighing. The stretcher’s weight is automatically subtracted from the measured 
41  
weight. The scale in the CT table of the Mobile Stroke Unit has been successfully used 
for more than 50 patients with no treatment delays. 
 
Figure 16: . A Ground-level scale and display (arrows) in the computed tomography (CT) suite of the 
hospital, allowing weighing of the patient during the handover procedure without additional transfer. 
 
B. A scale integrated into the CT table of the Mobile Stroke Unit for automatic weighing of the patient. 
Arrow shows the display of the scale. 
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2.2.3 Comparing Reported, Estimated, and 
Measured Weights 
In the hospital’s CT suite, an independent rater asked the patients to report their own 
weight. If the patient was aphasic or otherwise unable to answer, the patient’s 
caregiver was asked to provide the weight. Next, the treating neurologist, who was 
unaware of either the reported or the measured weight, estimated the patient’s 
weight. Deviations of reported and estimated weights from measured weights were 





Statistical analyses were performed with IBM SPSS Statistics for Windows, version 
23.0.0.2 (IBM Corporation, Armonk, NY, USA; released 2015). The difference between 
the absolute values of deviations of reported and estimated weights from measured 
weights were analyzed with t tests for paired variables. 












This study included 100 consecutive patients with suspected acute stroke (53 females, 
































































Ten of the patients had stroke mimics, and 2 had primary intracranial hemorrhage. 
 
IVT, mechanical recanalization, or both were necessary for 24 patients, including 3 who 
experienced secondary hemorrhagic transformation or bleeding into the infarct, one 
of these with symptomatic bleeding. 

















frequency percent cumulative percent 
Nein 97 97,0 97,0 













The median National Institutes of Health Stroke Scale score (NIHSS) was 4 
(range, 0–40) at the time of admission Table 7. 
NIHSS frequency valid percent cumulative percent 
0 8 8,0 8,0 
1 10 10,0 18,0 
2 27 27,0 45,0 
3 1 1,0 46,0 
4 16 16,0 62,0 
5 3 3,0 64,0 
6 9 9,0 74,0 
8 6 6,0 80,0 
10 4 4,0 84,0 
12 3 3,0 87,0 
14 4 4,0 91,0 
16 4 4,0 95,0 
17 2 2,0 97,0 
18 2 2,0 99,0 
40 18,0 1,0 100,0 
total 100 100,0 
 
Table 7: NIHSS score at admission 
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frequency valid percent cumulative percent 
0 46 46,0 46,0 
1 9 9,0 55,0 
2 16 16,0 71,0 
3 3 16,0 74,0 
4 10 10,0 84,0 
5 1 1,0 85,0 
6 7 7,0 92,0 
8 1 1,0 93,0 
10 2 2,0 95,0 
12 2 2,0 97,0 
14 1 1,0 98,0 
16 1 1,0 99,0 
100 1 1,0 100,0 
total 100 100,0 
 
 
Table 8: NIHSS score at discharge 
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The median modified Rankin Scale score was 2 (range, 0–5) at the time of admission. 
 
mRS frequency Valid percent cumulative percent 
0 11 11,0 11,0 
1 36 36,0 47,0 
2 28 28,0 75,0 
3 11 11,0 86,0 
4 12 12,0 98,0 








Table 9: Rankin score at admission 
 
and 1 (range, 0–6) at the time of discharge. 
 
 
mRS frequency valid percent cumulative percent 
0 46 46,0 46,0 
1 26 26,0 72,0 
2 17 17,0 89,0 
3 8 8,0 97,0 
4 2 2,0 99,0 








Table 10: Rankin score at admission. 
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3.1 Estimated and Actual Weights 
Eight patients could not report their own weight because of aphasia (n = 7) 4 women 
and 3 men)or agitation (n = 1 woman). 
The median measured weight of the patients was 76.0 kg (range, 44.0–133.4 kg). 
 
Weighing of all 100 patients was performed during the routine handover procedure 
without delays. 
Patients’ characteristics are displayed in Table 11. 
 
Age, years 71.5 (20-90) 
Men 47 
Women 53 
NIHHS score at admission 4 (0-40) 
mRS score at admission 2 (0-5) 
NIHHS score at discharge 1 (0-40) 
mRS score at discharge 1 (0-6) 
Patients unable to report weight 8 
Average measured weight, kg 76.0 (44.0-133.4) 
Stroke mimics 10 
IVT, mechanical recanalization, or both 24 
Primary ICH 2 
Secondary ICH 3 
Death 1 
Continuous data shown as median (range), expect if indicated otherwise. NIHSS, 
National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; IVT, 
intravenous thrombolysis; ICH, intracranial hemorrhage. 
Table 11 Patients’ characteristics (n:100). 
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We have studied the reported, estimated, and measured weights in two subgroups 
(men and women): 
The median measured weight of women was 69 kg (range 44.0- 128.8 kg) with 
standard deviation 14.91. 
The median measured weight of men was 85.0 kg (range 58.0-133.4 kg) with standard 
deviation 14.59. 
The median measured weight of men was 16 .0 kg more than women. 
The age of patients varied from 20 years to 92 years with median age, 71.5 years and 
standard deviation 14.77. 
The age of women varied from 20 years to 92 with median age 75 years and standard 
deviation 15.33. 
The age of men varied from 20 years to 91 with median age 63 years and standard 
deviation 13.18. 




 Age - years weight reported by 
the patient kg 
weights estimated 




available 47 44 47 47 
unavailable 0 3 0 0 
median 63,00 85,50 84,00 85,00 
standard deviation 13,18 13,959 13,230 14,590 
minimum 20 60 57 54 
maximum 91 136 140 133,4 
 
Table 12: women’s characteristics (age, reported, estimated, and measured weights). 
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 Age - years weight reported by 
the patient kg 
weights estimated 
by the physician kg 
Measured 
Weight kg 
available 53 48 53 53 
unavailable 0 5 0 0 
median 75,00 69,50 70,00 69,00 
standard deviation 15.332 14,643 12,890 14,9190 
minimum 20 47 40 44,0 
maximum 92 135 120 128,8 
 





 Age- years weight reported by 
the patient kg 
weights estimated 




available 100 92 100 100 
unavailable 0 8 0 0 
median 71,50 73,00 77,00 76,00 
standard deviation 14,771 15,515 14,082 16,329 
minimum 20 47 40 44,0 
maximum 92 136 140 133,4 
 
Table 14: patients’ characteristics (age,reported , estimated, and measured weights). 
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3.2 Comparison between Estimated and 
Measured Weight 
The weights estimated by the physician diverged from actual weights by 10% or more 
for 27 patients and by 20% or more for 6 patients. In absolute values, 17 estimated 
weights deviated from measured weights by 10 kg or more; the extremes of estimated 
weights were 22 kg too light and 16.8 kg too heavy (Fig. 19a). For the 92 patients for 
whom weights could be reported, 12 weights (13%) diverged by 10% or more from 
measured weights; there were no deviations of 20% or more. In absolute values, the 
weights of 3 patients (3.3%) deviated by 10 kg or more from measured weights; the 
extremes of estimated weights were 17.6 kg too light and 11 kg too heavy (Figure 19b). 
Reported weights differed significantly less from measured 
 
weights (mean deviation, 4.1 ± 3.1 kg) than did estimated weights (5.7 ± 4.4 kg; p 







Figure 19: Modified Bland-Altman plot showing deviation of weight estimated by health care professionals 
from measured weight 
 
(a) and deviation of weight reported by the patients from measured weight. (b) The solid lines indicate means 
and standard deviations; the dashed lines, the 1.96-fold standard deviations. Plot shows weight estimated by 
the health care professionals (c) and weight reported by the patients against measured weight (d). The solid 
lines display simple linear regression; the dashed lines, the equality of estimated and measured weights. 
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The dosage of tissue plasminogen activator (tPA) depends on the reported weight by 
patients was incorrect in 39% of patients, and it was 13.4% more in women rather 




 Frequency Percent 
Incorrect dose 15 31,9 
Correct dose 29 61,7 
total 44 93,6 
unavailable 3 6,4 
total 47 100,0 
 





 Frequency Percent 
Incorrect dose 24 45,3 
Correct dose 24 45,3 
total 48 90,6 
unavailable 5 9,4 
total 53 100 
 





 Frequency Percent 
Incorrect dose 39 39 
Correct dose 53 53,0 
total 92 92,0 
unavailable 8 8,0 
total 100 100 
 




This prospective study shows that weighing acute stroke patients in the stroke 
treatment room or in a mobile stroke unit is feasible without treatment delays and 
that deviations between estimated and real weights are substantial: estimations of 
weight by health care professionals diverged by 10% or more from actual weight for 
27% of patients. 
These results are consistent with the findings of earlier studies suggesting that 
estimation is prone to severe errors. 
Breuer et al. (107) in WAIST study found variations of as much as 42% between 
estimated and actual weights; the deviation was more than 10% for every third patient, 
it is a prospective observational monocenter study. It included 109 patient who 
received IVT for acute ischemic stroke (AIS) at (University Hospital Erlangen, Germany), 
body weight was estimated before the therapy with tPA independently by 2 physicians, 
2 emergency nurses, and a neuroradiological technical assistant. 
All patients after the Therapy with tPA were weighed as early as possible within 24 
hours. A standard calibrated licensed scale was used when they were able to stand 
(Seca, Hamburg, Germany; Model 701). And the bedridden patients were weighed on 
a special bed scale calibrated and validated for the use for patient weighing (Seca; 
Model 657). 
Clinical outcome was evaluated at 90 days to evaluate dosing errors. 
 
Estimation errors rates ranged from 20.8% (patient's own estimation) up to 38.2% 
(treating physician) and 42.2% (emergency nurse). 
29 patients received an Alteplase dosage diverging >10% from the optimal dose. 
Twelve were under- and 17 overdosed. 
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Underdosage accompanied with worse outcome in multivariate analysis. 
 
This study proved that measuring bodyweight before Alteplase therapy remains 
challenging. Led to dose errors in one-third of patients and observed impact on 






















Similar results were reported by Lorenz et al. (112) and Sahlas et al.(109) 
 
Because the dosage of tPA is based on the patient’s weight, the risk of misdosing exists 
for a large number of patients. 
 
Our findings of frequent incorrect estimates led us to question whether weight 
assessment based on estimation or on nomograms alone is still justified. 
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While the current dosage of tPA has been approved due to the results of the NINDS 
trial, there remain uncertainties regarding the ideal dosage and dosage corridor. Data 
from registries do not indicate a substantial risk (113). One recent study, which 
assessed patients’ actual weights after IVT, compared a standard dose group with 
groups receiving overdosage or underdosage of IVT; the study found no evidence that 
misdosage had any effects on clinical outcome. However, these findings could be 
explained by the fact that this relatively small study (n = 272) may have been 
underpowered to address such a study question (114). On the other hand, it is 
implausible to assume that misdosing of a highly effective and weight-adapted drug 
would have no effect on clinical results, because a dose-effect relationship can be 
expected. 
This suggestion is supported by a growing body of evidence indicating negative 
outcomes due to misdosing. 
Sahlas et al. [109] reported that overdosed patients exhibited impaired outcome and 
more episodes of intracranial bleeding, and Breuer et al. [107] found that precise 
dosages (0.8–1.0 mg/kg) are required for optimal recanalization. 
Similarly, Wahlgren et al. (108) reported that underdosage may be associated with 
impaired clinical outcome. 
Compared with nonobese subjects, obese patients exhibit a lower rate of intracranial 
hemorrhage because of systematic underdosing of tPA (the ceiling dose is 90 mg). Such 
underdosing reduces both the beneficial and the adverse pharmacological effects of 
the drug (115). 
Seet et.al (90) also reported about decreasing rates of intracranial hemorrhage in 
obese patients because of low dose of rt-PA. 
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A survey of 119 German stroke units found that 80.5% always or frequently estimate 
patients’ weights. Only 4.2% of these stroke units always weigh patients, and an 
additional 7.6% frequently weigh them. 
The most frequent answers to the question of why patients are not weighed were the 
following: “No opportunity to weigh patients in supine position;” “time delay;” “scale 
is unpractical;” “scale is too far away;” and “no scale is available.” (106). 
Similar results were found in the SITS-ISTR Registry, which reported that only 14.6% of 
patients were weighed; weights were estimated for 84.6% of patients (105). 
Nomograms based on anthropometric data, such as height, waist circumference, and 
hip size, have been proposed for overcoming the problems of imprecise weight 
estimates, but such calculating devices are time-consuming. Furthermore, even with 
this approach, deviations of more than 10% have been reported (115). 
Moreover, these surveys indicate that nomograms are almost never used in actual 
patient care, at least in the countries in which the survey was performed. 
The recently published ENCHANTED trial, involving predominantly Asian patients 
compared low dose (0.6 mg/kg) versus standard dose of tPA and did not show the 
noninferiority of the lower dose with respect to death and disability at 90 days, but 
there were significantly fewer symptomatic intracranial hemorrhages (116). 
Another finding of these surveys was that many hospitals do not have scales suitable 
for weighing acute stroke patients. This fact could be due to the potentially high costs 
of such scales. 
The commercially available ground-level scale for hospital use and the scale integrated 
in the CT table cost EUR/USD 3,000 each. 
However, overdosing of tPA is also costly; over time, avoiding these costs could 
conceivably offset the cost of a scale. 
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Additionally, avoiding overdosing would allow safer and more effective treatment of 
acute stroke patients. 
As our study shows, using the ground-level scale or a scale integrated into the CT table 
is applicable and does not increase delays in acute stroke management; therefore, 
there is no reason to omit actual weighing of the thrombolysis candidate. 
This study has some limitations. Although we were able to demonstrate substantial 
aberrations between estimated and measured weights, we could not determine 
whether these aberrations would lead to impaired clinical outcome. Without blinded 
randomization between estimated weights and measured weights it is not possible to 
know whether differences between them have an effect on outcome. 
On the other hand, for ethical reasons, it is very unlikely that such a randomized trial 
could be performed once a scale has already been installed. 
In conclusion, in this prospective study on weight assessment in acute stroke patients, 
weighing patients with acute stroke on a ground-level scale or a scale integrated into 
the CT table is feasible and avoids the treatment delays associated with additional 
transfer of the patients. 
Estimates of patients’ weight by health care professionals and reports of weight by the 
patients themselves diverge substantially from patients’ measured weights. 
Measuring patients’ weight with a scale would avoid these deviations, improve the 
accuracy of tPA dosing, decrease complication and improve outcome. 
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